序贯添加认知行为治疗或抗抑郁药对未缓解抑郁症成人的获益
本研究纳入初始单药治疗12周未缓解的抑郁症成人,序贯添加另一种治疗12周。单药有应答但未缓解者联合治疗缓解率61%,高于无应答者的41%;CBT加药组缓解率89%高于药物加CBT组的53%,但无应答者两序贯方案结局相似。
要点
- 单药有应答但未缓解者,序贯联合治疗缓解率高于无应答者。
- 有应答但未缓解者中,CBT后加药缓解率高于药物后加CBT。
- 无应答者两序贯方案应答和缓解率相似,焦虑水平高预测结局差。
核心结论
- CBT与抗抑郁药序贯联合的顺序似乎不影响总体结局。
- 对CBT未缓解者添加抗抑郁药有效,对药物单药未缓解者添加CBT亦有效。
- 对一种治疗模态无应答者,应考虑添加替代模态。
研究设计与样本
- 研究为随机分配后序贯联合治疗设计。
- 既往未治疗的抑郁症成人随机接受艾司西酞普兰、度洛西汀或CBT单药治疗12周。
- 未缓解者进入额外12周联合治疗:CBT未缓解者加艾司西酞普兰,抗抑郁药未缓解者加CBT。
- 联合治疗应答者进入18个月随访评估复发风险。
- 共112例单药未缓解者进入联合治疗,其中41例单药有应答但未缓解,71例无应答。
主要发现
- 联合治疗后总缓解率:单药有应答但未缓解者为61%,单药无应答者为41%,差异显著。
- 单药有应答但未缓解者中,CBT加药组缓解率为89%,药物加CBT组为53%。
- 单药无应答者中,两治疗组应答和缓解率相似。
- 单药治疗前和联合治疗前焦虑水平较高均预测两治疗组结局较差。
临床怎么用
- 对单药治疗有部分应答但未缓解者,序贯联合治疗可能获得较高缓解率。
- 对CBT未缓解者可添加抗抑郁药,对抗抑郁药未缓解者可添加CBT。
- 基线及联合治疗前焦虑水平较高者需关注较差结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adults with major depressive disorder frequently do not achieve remission with an initial treatment. Addition of psychotherapy for patients who do not achieve remission with antidepressant medication alone can target residual symptoms and protect against recurrence, but the utility of adding antidepressant medication after nonremission with cognitive-behavioral therapy (CBT) has received little study. The authors aimed to evaluate the acute and long-term outcomes resulting from both sequences of combination treatments. METHODS: Previously untreated adults with major depression who were randomly assigned to receive escitalopram, duloxetine, or CBT monotherapy and completed 12 weeks of treatment without achieving remission entered an additional 12 weeks of combination treatment. For patients who did not achieve remission with CBT, escitalopram was added (CBT plus medication group) to their treatment, and for those who did not achieve remission with an antidepressant, CBT was added (medication plus CBT group) to their treatment. Patients who responded to the combination treatment entered an 18-month follow-up phase to assess risk of recurrence. RESULTS: A total of 112 patients who did not achieve remission with a monotherapy entered combination treatment (41 who responded to monotherapy but did not achieve remission and 71 who did not respond to monotherapy). Overall, remission rates after subsequent combination therapy were significantly higher among patients who responded to monotherapy but did not achieve remission (61%) than among patients who did not respond to monotherapy (41%). Among patients who responded to monotherapy but did not achieve remission, the remission rate in the CBT plus medication group (89%) was higher than in the medication plus CBT group (53%). However, among patients whose depression did not respond to monotherapy, rates of response and remission were similar between the treatment arms. Higher levels of anxiety, both prior to monotherapy and prior to beginning combination treatment, predicted poorer outcomes for both treatment groups. CONCLUSIONS: The order in which CBT and antidepressant medication were sequentially combined did not appear to affect outcomes. Addition of an antidepressant is an effective approach to treating residual symptoms for patients who do not achieve remission with CBT, as is adding CBT after antidepressant monotherapy. Patients who do not respond to one treatment modality warrant consideration for addition of the alternative modality.
引用
- Dunlop BW, LoParo D, Kinkead B, et al. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. Am J Psychiatry. 2019. PMID: 30764648. doi:10.1176/appi.ajp.2018.18091075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。